ADCs are a hot topic in drug development even though only two have been approved so far and one of those withdrawn. Regardless, Roche's (Genentech) T-DM1 is widely expected to gain approval in 2013 an dmany many more ADCs are in development in a large number of companies.
With that as backdrop, Synthon has just opened a new ADC facility in Nijmegan, Netherlands. The facility is geared to bring Synthon's internal pipeline of HER2-ADCs to market (same target as T-DM1). HER2 is overexpressed in breast cancers and non-small cell lung cancers. Synthon refers to its therapy as second generation ADCs. Synthon also has other ADCs in development (at least two other targets) and has not closed the door on partnering with other companies to manufacture these products.
Posted by Bruce Lehr Jan 27th 2013.